Spectral Medical (Edtxf) (TSE:EDT) has released an update.
Spectral Medical Inc. has reported progress in its Phase 3 Tigris trial for treating septic shock, with a record 93 patients enrolled to date and robust enrollment throughout February. The trial, which evaluates the efficacy of the Polymyxin B Hemoperfusion device in treating endotoxemia and septic shock, is approaching its final enrollment phase. This momentum comes as Spectral prepares for an Investigator Meeting in March, coinciding with a critical care conference, and continues expansion with new trial sites and increased site onboarding.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
